Anger amplifies clinical pain in women with and without fibromyalgia

Millions at risk from invisible dangers in the home this winter


Researchers from Utrecht University who studied the effect of negative emotions on pain perception in women with and without fibromyalgia found that anger and sadness amplified pain equally in both groups. Full findings are now online and will publish in the October print issue of Arthritis Care & Research, a journal of the American College of Rheumatology.

Fibromyalgia (FM), a chronic pain condition, has among the largest impact of all rheumatic and chronic pain conditions. In addition to chronic, widespread pain, patients report accompanying symptoms such as fatigue, functional disability, and psychological distress. FM is thought to involve heightened pain sensitivity to a variety of psychophysical and emotional stimuli, with negative emotions believed to be experienced more strongly in FM patients than in the general population.

The Utrecht team theorized that specific negative emotions such as sadness and anger also would increase pain more in women with FM than in healthy women. Their study examined the effects of experimentally-induced anger and sadness on self-reported clinical and experimentally-induced pain in women with and without FM. Participants consisted of 62 women with FM and 59 women without FM. Both groups were asked to recall a neutral situation, followed by recalling both an anger-inducing and a sadness-inducing situation, in counterbalanced order. The effect of these emotions on pain responses (non-induced clinical pain and experimentally-induced sensory threshold, pain threshold, and pain tolerance) was analyzed with a repeated-measures analysis of variance.

Self-reported clinical pain always preceded the experimentally-induced pain assessments and consisted of reporting current pain levels (“now, at this moment”) on a scale ranging from “no pain at all” to “intolerable pain.” Clinical pain reports were analyzed in women with FM only. Electrical pain induction was used to assess experimentally-induced pain. Participants pressed a button when they felt the current (sensory threshold) and when it became painful (pain threshold) and intolerable (pain tolerance). Four pain assessments were conducted per condition, and very high internal consistencies were obtained.

More pain was indicated by both the clinical pain reports in women with FM and pain threshold and tolerance in both groups in response to anger and sadness induction. Sadness reactivity predicted clinical pain responses. Anger reactivity predicted both clinical and electrically-stimulated pain responses.

Both women with and women without FM manifested increased pain in response to the induction of both anger and sadness, and greater emotional reactivity was associated with a greater pain response. “We found no convincing evidence for a larger pain response to anger or sadness in either study group (women with, or without FM), said study leader Henriët van Middendorp, Ph.D. “In women with FM, sensitivity was roughly the same for anger and sadness.”

Dr. van Middendorp concludes, “Emotional sensitization of pain may be especially detrimental in people who already have high pain levels. Research should test techniques to facilitate better emotion regulation, emotional awareness, experiencing, and processing.”

In a related study, a research team from Radboud University Nijmegen Medical Centre found that tailored cognitive-behavioral therapy (CBT) and exercise training tailored to pain-avoidance or pain-persistence patterns at a relatively early stage after diagnosis is likely to promote beneficial treatment outcomes for high-risk patients with FM.

The Nijmegen team evaluated the effects of this approach in a randomized controlled trial. The study compared a waiting list control condition (WLC) with patients in a treatment condition (TC) to demonstrate improvements in physical and psychological functioning and in the overall impact of FM.

High-risk patients were selected and classified into 2 groups (84 patients were assigned to a pain-avoidance group and 74 patients to the pain-persistence group) and subsequently randomized to either the TC or WLC. Treatment consisted of 16 sessions of CBT and exercise training, tailored to the patient’s specific cognitive behavioral pattern, delivered within 10 weeks. Physical and psychological functioning and impact of FM were assessed at baseline, post-treatment, and 6-month follow-up.

The treatment effects were significant, showing notable positive differences in physical (pain, fatigue, and functional disability) and psychological (negative mood and anxiety) functioning, and impact of FM for the TC in comparison with the WLC. Clinically relevant improvement was found among patients in the TC group.

“Our results demonstrate that offering high-risk FM patients a treatment tailored to their cognitive behavioral patterns at an early stage after the diagnosis is effective in improving both short-and long-term physical and psychological outcomes,” says junior investigator Saskia van Koulil. “Supporting evidence of the effectiveness of our tailored treatment was found with regard to the follow-up assessments and the low dropout rates. The effects were overall maintained at 6 months, suggesting that patients continued to benefit from the treatment.”

Cognitive behavior therapy significantly reduced depression and anxiety in chronic pain patients

MS and depression


The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) has shown that Acceptance and Commitment Therapy, a form of cognitive behavioural therapy (CBT) that focuses on psychological flexibility and behaviour change, provided a significant reduction in self-reported depression and anxiety among patients participating in a pain rehabilitation programme.

This treatment also resulted in significant increases in self-efficacy, activity engagement and pain acceptance.

To assess the potential benefits of an 8-week programme of group Acceptance and Commitment Therapy (ACT) in people with persistent pain, measures of pain acceptance and activity engagement were taken using the Chronic Pain Acceptance Questionnaire. Measures of psychological distress using the Hospital Anxiety and Depression Scale and self-efficacy were also taken at assessment, on the final day of the programme, and at the follow up six-month review.

For those chronic pain patients with scores at all three time points, there were statistically significant improvements in all parameters between baseline and at six-months follow-up, including the change in mean score of depression, anxiety, self-efficacy, activity engagement and pain willingness (p<0.001).

“To further validate the role of ACT in the treatment of chronic pain, specifically in a rheumatology context, a randomised controlled clinical trial that includes measures of physical and social functioning within a Rheumatology service would be desirable,” said lead author Dr. Noirin Nealon Lennox from Ulster University in Northern Ireland.

ACT is a form of CBT that includes a specific therapeutic process referred to as “psychological flexibility”. ACT focuses on behaviour change consistent with patients’ core values rather than targeting symptom reduction alone. Evidence for this approach to the treatment of chronic pain has been mounting since the mid 2000’s. A previous systematic review had concluded that ACT is efficacious for enhancing physical function and decreasing distress among adults with chronic pain attending a pain rehabilitation programme.

In this study, patients were referred into the ACT programme by three consultant rheumatologists over a five-year period. Over one hundred patients’ outcome measures were available for a retrospective analysis.

Mind over matter: Beating pain and painkillers

Women and pain
Women and pain


With nearly one-third of Americans suffering from chronic pain, prescription opioid painkillers have become the leading form of treatment for this debilitating condition. Unfortunately, misuse of prescription opioids can lead to serious side effects—including death by overdose. A new treatment developed by University of Utah researcher Eric Garland has shown to not only lower pain but also decrease prescription opioid misuse among chronic pain patients.

Results of a study by Garland published online Feb. 3 in the Journal of Consulting and Clinical Psychology, showed that the new treatment led to a 63 percent reduction in opioid misuse, compared to a 32 percent reduction among participants of a conventional support group. Additionally, participants in the new treatment group experienced a 22 percent reduction in pain-related impairment, which lasted for three months after the end of treatment.

The new intervention, called Mindfulness-Oriented Recovery Enhancement, or MORE, is designed to train people to respond differently to pain, stress and opioid-related cues.

MORE targets the underlying processes involved in chronic pain and opioid misuse by combining three therapeutic components: mindfulness training, reappraisal and savoring.

  • Mindfulness involves training the mind to increase awareness, gain control over one’s attention and regulate automatic habits.
  • Reappraisal is the process of reframing the meaning of a stressful or adverse event in such a way as to see it as purposeful or growth promoting.
  • Savoring is the process of learning to focus attention on positive events to increase one’s sensitivity to naturally rewarding experiences, such as enjoying a beautiful nature scene or experiencing a sense of connection with a loved one.

“Mental interventions can address physical problems, like pain, on both psychological and biological levels because the mind and body are interconnected,” Garland said. “Anything that happens in the brain happens in the body—so by changing brain functioning, you alter the functioning of the body.”

To test the treatment, 115 chronic pain patients were randomly assigned to eight weeks of either MORE or conventional support group therapy, and outcomes were measured through questionnaires at pre- and post-treatment, and again at a three-month follow-up. Nearly three-quarters of the group misused opioid painkillers before starting the program by taking higher doses than prescribed, using opioids to alleviate stress and anxiety or another method of unauthorized self-medication with opioids.

Among the skills taught by MORE were a daily 15-minute mindfulness practice session guided by a CD and three minutes of mindful breathing prior to taking opioid medication. This practice was intended to increase awareness of opioid craving—helping participants clarify whether opioid use was driven by urges versus a legitimate need for pain relief.

“People who are in chronic pain need relief, and opioids are medically appropriate for many individuals,” Garland said. “However, a new option is needed because existing treatments may not adequately alleviate pain while avoiding the problems that stem from chronic opioid use.”

MORE is currently being tested in a pilot brain imaging trial as a smoking cessation treatment, and there are plans to test the intervention with people suffering from mental health problems who also have alcohol addiction. Further testing on active-duty soldiers with chronic pain and a larger trial among civilians is planned. If studies continue to demonstrate positive outcomes, MORE could be prescribed by doctors as an adjunct to traditional pain management services.

Coping with Pain: A Mindfulness Meditation

Guided Mindfulness Meditation on Coping with Pain (20 minutes) - YouTube


This guided meditation session is designed for people who have practiced meditation in the past. Meditation has been shown to have many health benefits, including reducing pain, enhancing the body’s immune system and improving mood.



Overlooked disease: Tens of thousands of people have problems at work

ankylosing spondylitis

Imagine your head pounding. And when you try to move, a door slams, or curtains are drawn it gets much worse. Ideally, you would like to crawl under your blanket in a dark and quiet room.

This is how it may feel for people suffering from migraine or frequent tension headaches. Untreated, a migraine attack may last for 4-72 hours, and tension headaches may potentially last for a week. In Denmark, it is estimated that approximately 770,000 people suffer from migraine or frequent tension headaches.

Now, for the first time, a new study from the University of Copenhagen shows specifically how migraine or frequent tension headaches affect the ability to work.  

“It is especially the ability to remember, make quick decisions and do hard physical work that cause difficulties for people with these headache disorders,” says Project Manager and author of the study Kirsten Nabe-Nielsen.

She hopes that the study will help to focus on the consequences which headaches may have for working life.  

“Migraine is the leading cause of functional impairment among people under the age of 50. And headaches have negative effects on sick leave and productivity. So, it would benefit workplaces to open their eyes to the untapped potential that you find here,” says Kirsten Nabe-Nielsen, adding:

“Indeed, we cannot afford not to take it seriously.”

If you ask the Danish working population, 24 per cent of women and 10 per cent of men suffer from migraines or frequent tension headaches.

The possibilities of adapting the work during headache attacks depend on the type of work you have, says Kirsten Nabe-Nielsen, stressing:

“So also in this context, there is a significant inequality in health.”

While people with academic jobs will often be able to go home a little earlier, work from home or choose to postpone the tasks that demand the highest concentration, other people, such as cleaning staff or nursing staff in old people’s homes, do not have the same opportunities to adjust the working hours or postpone the tasks to be solved. Instead, they may have to call in sick.

According to Kirsten Nabe-Nielsen, it takes creativity on the part of the manager and the employees to find out which solutions may be helpful:

“It is about having a good overview of the tasks that need to be solved, and then having a talk as to the best way to arrange a work day. For example, there may be tasks that can be performed later in the day, or that can be solved at a leisurely pace or in a quiet space until the pain has gone.”

“I am going to lay down”

Kirsten Nabe-Nielsen believes that headache disorders such as migraine and frequent headaches are an overlooked epidemic.

“We are stuck with the idea of the character Maude from the Danish TV series Matador saying ‘I am going to lay down’ whenever she is a bit stressed,” she says, explaining: 

“Most people have experienced headaches. Therefore, it may be difficult to understand how debilitating migraine and frequent headaches may be for a colleague, friend or family member. People still have the notion that it will be sufficient to swallow a pill.”

Kirsten Nabe-Nielsen believes that there is a lack of knowledge in the general population about the importance of headache disorders. The same applies to the fact that taking too many painkillers to soothe the headache may actually lead to more headaches.

“Some studies show that headaches are the second-most common cause of sick leave – surpassed only by infectious diseases. Therefore, headache disorders carry large personal and socio-economic costs,” says Kirsten Nabe-Nielsen.

Associated with depressive symptoms and muscular pain

The researchers have used self-reported information from more than 5,000 active Danes with different educational backgrounds – from people with long academic educations to unskilled workers.

“It is new that we combine information about migraine and frequent headaches with the participants’ use of painkillers and with their description of the ability to cope with seven different, specific requirements at work,” says Kirsten Nabe-Nielsen.

The participants also answered questions about their health, depressive symptoms and pain in muscles and joints.

Here, the researchers found that depressive symptoms and pain in muscles and joints play an important role for the context between headache disorders and the ability to work.

“Our results indicate that the handling of depressive symptoms and pain in the musculoskeletal system may be an important factor in improving the ability to work among people with headache disorders,” says Kirsten Nabe-Nielsen.

Previous studies support the finding that headaches, muscle and joint pain coincide with depressive symptoms. Among other things, you may see mood changes, and neck pain may be a warning sign of a migraine attack, just as frequent headache attacks may affect the mood negatively.

Under- and overmedication

The researchers find the lowest ability to work in the group of headache sufferers who do not use painkillers at all and the group who use painkillers on a daily basis.

“This raises the question whether these two groups are undertreated and overtreated, respectively,” says Kirsten Nabe-Nielsen.

According to Kirsten Nabe-Nielsen, it seems to indicate that the group taking painkillers on a daily basis may not receive a treatment that works as intended – and they might even suffer from medication overuse headaches.

“On the other hand, when you look at the group who does not take medication at all, it seems to indicate that they are undermedicated. And maybe it has to do with the fact that they do not consider their illness to be severe enough to seek medical attention – but that is just our guess,” says Kirsten Nabe-Nielsen.  

Facts: What are migraines and frequent headaches?

The two most common forms of headaches are migraine and tension headache.

Migraine is characterised by bouts of moderate or severe pulsating headache accompanied by nausea, vomiting and sensitivity to light and sound. Chronic migraine occurs more than 14 days a month.

Tension headache is characterised by mild to severe pain on both sides of the head. Nausea and vomiting are usually absent. Chronic headache occurs more than 14 days a month.